Inside Peptides
Search
Menu

Growth Hormone Axis & Secretagogue Peptides

Growth hormone axis peptide research examines the somatotropic endocrinology governing growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. Explores synthetic GHRH analogues, ghrelin receptor secretagogues, clinical lipodystrophy trials, and anti-doping regulations.

Endocrine diagram of hypothalamic-pituitary somatotroph axis showing GHRH, somatostatin, and ghrelin secretagogue receptors
Pituitary somatotrophs integrate GHRH stimulation, somatostatin inhibition, and GHSR secretagogue pulses.

Field Summary & Status

Strong Evidence for Approved Drugs; Early Human for Unapproved
Field Maturity Clinically Validated / High for Specific Indications
Primary Receptors GHRH-R, GHSR-1a (Ghrelin Receptor), SSTR2/5
Target Tissues Anterior Pituitary Somatotrophs, Liver, Adipose Tissue, Skeletal Muscle
Key Approved Medicines Tesamorelin (Egrifta), Somatropin (recombinant GH), Octreotide
Lead Investigational Classes CJC-1295 (DAC:GRF), Ipamorelin, Macimorelin
Last Updated 2026-10-10

Somatotropic Endocrinology & Secretagogue Modulation

The somatotropic axis is governed by anterior pituitary growth hormone (GH) secretion, which stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1). Natural GH release occurs in pulsatile bursts coordinated by two opposing hypothalamic hormones: Growth Hormone-Releasing Hormone (GHRH, stimulatory) and Somatostatin (inhibitory).

In the late 1990s, discovery of the growth hormone secretagogue receptor (GHSR-1a) and its endogenous ligand ghrelin revealed a third regulatory input. Synthetic peptides targeting this axis divide into GHRH receptor agonists (which preserve feedback loops) and GHSR secretagogues (which trigger potent pulses).

While tesamorelin achieved FDA approval for visceral fat reduction in HIV-associated lipodystrophy, underground marketing of unapproved analogues (CJC-1295, ipamorelin) for bodybuilding is widespread and strictly banned under WADA Category S2.

Biological Systems & Signaling Mechanisms

Growth-hormone-producing cells in the pituitary gland receive signals through cell-surface receptors, including GPCRs. These signals help control the release of growth hormone (GH) from storage inside the cells.

Detailed biological signaling pathway schematic for Growth Hormone Axis & Secretagogue Peptides
Integrated biological signaling pathways and physiological mechanisms in Growth Hormone Axis & Secretagogue Peptides.

GHRH Receptor Gs / cAMP Cascade

GHRH binding stimulates adenylyl cyclase and cAMP, activating PKA to promote somatotroph proliferation and GH transcription.

Evidence Domain: Endocrine Physiology

GHSR-1a Gq / Calcium Mobilization

Ghrelin secretagogues activate phospholipase C, mobilizing IP3 and intracellular Ca2+ to trigger immediate granule exocytosis.

Evidence Domain: Receptor Pharmacology

Somatostatin Gi Suppression

Somatostatin activates Gi-coupled receptors, inhibiting adenylyl cyclase and lowering intracellular calcium to blunt GH pulses.

Evidence Domain: Feedback Regulation

Peptide Classes & Molecular Targets

Compounds modulating the somatotropic axis divide into physiological GHRH analogues and ghrelin receptor mimetics.

Synthetic GHRH Analogues

Target: Tesamorelin, CJC-1295 (Modified GRF 1-29)
FDA-Approved (Tesamorelin) / Discontinued (CJC-1295)
Classification Endogenous / Synthetic
Clinical Standing FDA-Approved (Tesamorelin) / Discontinued (CJC-1295)
Physiological & Pharmacological Action:

Peptides modeled on GHRH(1-29) or full-length GHRH(1-44) engineered for enzymatic stability.

Key Representative Agents: Tesamorelin, CJC-1295 (Modified GRF 1-29)

Growth Hormone Secretagogues (GHSR-1a Agonists)

Target: Ipamorelin, GHRP-6, GHRP-2
Discontinued Clinical Trials; WADA Prohibited
Classification Endogenous / Synthetic
Clinical Standing Discontinued Clinical Trials; WADA Prohibited
Physiological & Pharmacological Action:

Small synthetic peptides and peptidomimetics that stimulate GH release via ghrelin receptors.

Key Representative Agents: Ipamorelin, GHRP-6, GHRP-2

Somatostatin Receptor Ligands (SRLs)

Target: Octreotide, Lanreotide, Pasireotide
FDA-Approved Oncology & Endocrine Standard
Classification Endogenous / Synthetic
Clinical Standing FDA-Approved Oncology & Endocrine Standard
Physiological & Pharmacological Action:

Cyclic peptides that suppress pathological GH and IGF-1 hypersecretion in acromegaly.

Key Representative Agents: Octreotide, Lanreotide, Pasireotide

Human Clinical Trials & Observational Data

Rigorous human trials demonstrate visceral adiposity reduction and growth hormone stimulation.

Trial / Study Identifier / Compound Phase & Cohort Status / Duration Primary Findings
TH9507 (Tesamorelin) in Patients With HIV-Associated Lipodystrophy
TH9507 (Tesamorelin) in Patients With HIV-Associated Lipodystrophy
NCT00123253 		Phase 3
412 HIV patients with abdominal fat accumulation, 26 weeks
 Completed Visceral adipose tissue decreased 15.2% with tesamorelin vs a 5.0% increase with placebo; triglycerides and cholesterol-to-HDL ratio also improved.
Published 2007
CJC-1295 Healthy Volunteer Pharmacokinetics
CJC-1295 Healthy Volunteer Pharmacokinetics
JCEM-2006 		Phase 1 Dose Escalation
66 healthy adults
 Completed Sustained multi-fold increases in mean trough GH and circulating IGF-1 lasting 6-14 days.
Published 2006

Approved Medicines vs. Investigational Compounds

Clear distinction between regulatory-approved prescription medicines and experimental candidates undergoing laboratory or early clinical testing.

Compound Target / Mechanism Regulatory Status Indications / Focus Sponsor / Developer
Tesamorelin (Egrifta / Egrifta SV) Approved Biological Target FDA/EMA Approved (2010) HIV-Associated Visceral Adiposity Theratechnologies
Octreotide (Sandostatin / Sandostatin LAR) Approved Biological Target FDA/EMA Approved (1988) Acromegaly & Neuroendocrine Tumors Novartis
Ipamorelin Selective GHSR-1a agonist Failed Phase 2 (Postoperative Ileus) Preclinical / Investigational Helse Sør-Øst / Novo Nordisk
CJC-1295 DAC Albumin-conjugated GHRH analogue Terminated Phase 2 Preclinical / Investigational ConjuChem

Safety Realities & Endocrine Risks

Chronically elevating growth hormone and IGF-1 carries documented systemic, oncological, and metabolic risks.

Impaired Glucose Tolerance & Insulin Resistance

Moderate to High

Excess growth hormone stimulates hepatic gluconeogenesis and antagonizes peripheral insulin action, raising fasting blood glucose.

Water Retention & Carpal Tunnel Syndrome

Mild to Moderate

Fluid retention, peripheral edema, and arthralgias commonly occur during somatotropic axis elevation.

WADA Prohibition & Anti-Doping Sanctions

Regulatory Disqualification

All GHRH analogues and GH secretagogues are classified under WADA Category S2, carrying multi-year athletic bans.

Unresolved Scientific Questions

Key mechanistic and translational questions currently under active scientific investigation.

Does long-term secretagogue therapy increase lifetime neoplasia risk?

Sustained elevation of circulating IGF-1 is epidemiologically linked to mitogenic cellular signaling; multi-decade safety data in healthy individuals is absent.

Is pulsatile GHSR stimulation superior to recombinant GH replacement?

Comparative trials evaluating secretagogues against daily recombinant somatropin for anti-aging endpoints lack clinical substantiation.

Evolution of Research & Milestones

Historical scientific breakthroughs, isolation events, structural discoveries, and regulatory milestones.

1982

GHRH Characterized

Guillemin and Vale independently isolate and sequence human pancreatic and hypothalamic GHRH.

1999

Ghrelin Discovered

Kojima identifies ghrelin as the natural endogenous ligand for GHSR-1a.

2010

Tesamorelin FDA Approval

Egrifta becomes the first GHRH analogue approved by the FDA.

Scientific References

Primary scientific publications, randomized controlled trials, and clinical consensus papers referenced in this field overview.

  1. Metabolic effects of a growth hormone-releasing factor in patients with HIV Falutz J et al. N Engl J Med 2007. N Engl J Med · 2007
    Source
  2. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults Teichman SL et al. J Clin Endocrinol Metab 2006. J Clin Endocrinol Metab · 2006
    Source
  3. Ipamorelin: the first selective growth hormone secretagogue Raun K et al. Eur J Endocrinol 1998. Eur J Endocrinol · 1998
    Source

Scientific & Educational Disclaimer

InsidePeptides.org provides scientific and educational analysis of peer-reviewed research for informational purposes only. This overview does not constitute medical advice, diagnosis, treatment, prescription, or clinical guidance. Incretin and metabolic peptide medicines require physician oversight, prescription authorization, and regular clinical monitoring. Never adjust, initiate, or discontinue prescribed treatments without direct consultation with a qualified medical specialist.